Dominari Holdings Inc. (DOMH) Stock

Dominari Holdings Inc., based in New York, New York, is a pioneering biotechnology firm dedicated to advancing small-molecule anti-cancer therapies. Specializing in oncology, the company boasts a robust pipeline focused on developing treatments for a variety of challenging cancers including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key candidates in their portfolio include DHA-dFdC, a promising drug candidate targeting pancreatic cancer, and KPC34, a small molecule therapy designed for both AML and acute lymphoblastic leukemia. In addition to their oncology focus, Dominari Holdings is actively engaged in developing an innovative antiviral platform aimed at inhibiting the replication of a range of viruses, including influenza, Ebolavirus, Marburg virus, and the coronaviruses responsible for diseases like SARS and MERS, as well as SARS-CoV-2, the virus causing COVID-19.

Founded in 1967 and formerly known as AIkido Pharma Inc., the company rebranded to Dominari Holdings Inc. in December 2022 to better reflect its expanded focus and strategic direction in biopharmaceutical innovation. Leveraging extensive licensing agreements with prestigious institutions such as the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences, Dominari Holdings continues to strengthen its position at the forefront of medical research and therapeutic development.b. With a commitment to addressing critical medical needs through cutting-edge science and strategic partnerships, Dominari Holdings is poised to make significant strides in improving outcomes for cancer patients and combating viral infections globally.

Headquartered in the heart of New York City, Dominari Holdings benefits from access to world-class research facilities and a thriving biotech ecosystem. The company's location underscores its strategic advantage in collaborating with top-tier academic and research institutions, fostering a collaborative environment conducive to driving innovation and accelerating the development of novel therapies. As Dominari Holdings advances its diverse pipeline of oncology treatments and expands its antiviral platform, it remains dedicated to pioneering new standards of care and contributing to the evolution of healthcare solutions worldwide.